HK1071066A1 - Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment - Google Patents
Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatmentInfo
- Publication number
- HK1071066A1 HK1071066A1 HK05103834.9A HK05103834A HK1071066A1 HK 1071066 A1 HK1071066 A1 HK 1071066A1 HK 05103834 A HK05103834 A HK 05103834A HK 1071066 A1 HK1071066 A1 HK 1071066A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bcl
- gossypol
- docetaxel
- paclitaxel
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29398301P | 2001-05-30 | 2001-05-30 | |
PCT/US2002/017206 WO2002097053A2 (fr) | 2001-05-30 | 2002-05-30 | Petits antagonistes moleculaires de proteines de la famille bcl2 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1071066A1 true HK1071066A1 (en) | 2005-07-08 |
Family
ID=31495521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05103834.9A HK1071066A1 (en) | 2001-05-30 | 2005-05-06 | Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment |
Country Status (18)
Country | Link |
---|---|
US (1) | US20030008924A1 (fr) |
EP (1) | EP1474121B1 (fr) |
JP (1) | JP2005515158A (fr) |
KR (1) | KR20040108528A (fr) |
CN (1) | CN1589135A (fr) |
AT (1) | ATE474568T1 (fr) |
AU (1) | AU2002305769B2 (fr) |
CA (1) | CA2449245A1 (fr) |
DE (1) | DE60237115D1 (fr) |
ES (1) | ES2349349T3 (fr) |
HK (1) | HK1071066A1 (fr) |
IL (1) | IL159110A0 (fr) |
MX (1) | MXPA03010977A (fr) |
NO (1) | NO20035301D0 (fr) |
NZ (1) | NZ529792A (fr) |
SG (1) | SG157952A1 (fr) |
WO (1) | WO2002097053A2 (fr) |
ZA (1) | ZA200309306B (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20023357D0 (no) * | 2002-04-19 | 2002-07-11 | Amersham Health As | Blanding |
US20070060615A1 (en) * | 2003-02-18 | 2007-03-15 | University Of South Florida | Method of Modulating Apoptosis Through Modulation of E2F1 |
ATE478663T1 (de) * | 2003-06-25 | 2010-09-15 | Burnham Inst | Analoga von apogossypol zur verwendung in der behandlung von krebs |
ZA200607956B (en) * | 2004-03-25 | 2008-02-27 | Univ Michigan | Gossypol co-crystals and the use thereof |
US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
CN101006065B (zh) | 2004-06-17 | 2012-07-11 | 英菲尼蒂发现公司 | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 |
US20060144723A1 (en) * | 2004-11-02 | 2006-07-06 | Mary Fuller | Device for securing valuables |
CA2600797A1 (fr) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Michigan | Inhibiteurs de chromen-4-one des elements anti-apoptotiques de la famille bcl-2 et utilisations |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
JP2009532354A (ja) * | 2006-03-30 | 2009-09-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ゴシポール共結晶の生産方法 |
CA2650520A1 (fr) | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Traitement de tumeurs exprimant ras |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
US7857804B2 (en) | 2006-09-01 | 2010-12-28 | Mccaffrey Timothy A | Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders |
US20090030088A1 (en) * | 2007-04-20 | 2009-01-29 | Clemson University | Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol |
WO2009036035A1 (fr) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Inhibiteurs de bcl-2 |
EP2205088B1 (fr) * | 2007-10-19 | 2018-02-21 | Burnham Institute for Medical Research | Inhibiteurs à base de naphtalène de protéines anti-apoptotiques |
EP2323648A4 (fr) * | 2008-08-14 | 2012-10-03 | Uab Research Foundation | Agents anti-arythmie, procédés pour leur utilisation, procédés pour leur identification et kits pertinents |
NZ593343A (en) * | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
US8937193B2 (en) * | 2009-10-08 | 2015-01-20 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
AU2011279303B2 (en) | 2010-07-12 | 2015-07-16 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
US8940737B2 (en) * | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP2794592A1 (fr) | 2011-12-23 | 2014-10-29 | Novartis AG | Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison |
CA2859869A1 (fr) | 2011-12-23 | 2013-06-27 | Novartis Ag | Composes inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison |
WO2013096049A1 (fr) | 2011-12-23 | 2013-06-27 | Novartis Ag | Composés permettant d'inhiber l'interaction de bcl-2 avec des partenaires de liaison |
JP2015503516A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Bcl2と結合相手の相互作用を阻害するための化合物 |
MX2014007732A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace. |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
WO2015123617A1 (fr) * | 2014-02-14 | 2015-08-20 | Arizona Board Of Regents For The University Of Arizona | Procédé pour réduire l'expression du gène bcl2 |
EP3708170A1 (fr) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions et procédés d'inhibition de protéines antiapoptotiques bcl-2 comme agents anti-âge |
CA2955972A1 (fr) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions et procedes de depletion selective de cellules senescentes |
CN105884634B (zh) * | 2015-01-05 | 2019-06-04 | 南开大学 | 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性 |
WO2017027845A1 (fr) | 2015-08-12 | 2017-02-16 | Memorial Sloan-Kettering Cancer Center | Dérivés phénylsulfonamido-benzofurane et leur utilisation dans le traitement de maladies prolifératives |
WO2017087810A1 (fr) * | 2015-11-20 | 2017-05-26 | Memorial Sloan-Kettering Cancer Center | Procédé de criblage d'inhibiteurs ciblant des voies de survie anti-apoptotiques |
CN108697667A (zh) | 2016-02-18 | 2018-10-23 | 延世大学校产学协力团 | 用于治疗癌症、含有多酚化合物作为活性成分的药物组合物 |
WO2017142348A1 (fr) * | 2016-02-18 | 2017-08-24 | 연세대학교 산학협력단 | Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif |
CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
CN109718377B (zh) * | 2017-10-31 | 2021-03-26 | 中国科学院脑科学与智能技术卓越创新中心 | KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用 |
CN112105360B (zh) | 2018-01-22 | 2024-01-30 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
WO2019221755A1 (fr) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Analogues de piperlongumine et leurs utilisations |
CN109876145A (zh) * | 2019-04-25 | 2019-06-14 | 中国科学院化学研究所 | 醋酸棉酚和化疗药的联合用药物 |
AU2020293230A1 (en) | 2019-06-12 | 2022-01-27 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein |
WO2022133030A1 (fr) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2 |
AU2022405016A1 (en) | 2021-12-09 | 2024-06-06 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806568A (en) * | 1985-09-12 | 1989-02-21 | Research Corporation | Gossypol derivatives |
US5026726A (en) * | 1989-12-11 | 1991-06-25 | The University Of New Mexico | Gossylic iminolactones and gossylic lactones and their anti-viral activities |
US5385936A (en) * | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
2002
- 2002-05-30 MX MXPA03010977A patent/MXPA03010977A/es active IP Right Grant
- 2002-05-30 NZ NZ529792A patent/NZ529792A/en not_active IP Right Cessation
- 2002-05-30 AU AU2002305769A patent/AU2002305769B2/en not_active Expired
- 2002-05-30 AT AT02734614T patent/ATE474568T1/de not_active IP Right Cessation
- 2002-05-30 WO PCT/US2002/017206 patent/WO2002097053A2/fr active IP Right Grant
- 2002-05-30 CA CA002449245A patent/CA2449245A1/fr not_active Abandoned
- 2002-05-30 IL IL15911002A patent/IL159110A0/xx unknown
- 2002-05-30 KR KR10-2003-7015683A patent/KR20040108528A/ko active IP Right Grant
- 2002-05-30 EP EP02734614A patent/EP1474121B1/fr not_active Expired - Lifetime
- 2002-05-30 SG SG200601161-3A patent/SG157952A1/en unknown
- 2002-05-30 DE DE60237115T patent/DE60237115D1/de not_active Expired - Lifetime
- 2002-05-30 JP JP2003500222A patent/JP2005515158A/ja active Pending
- 2002-05-30 US US10/158,769 patent/US20030008924A1/en not_active Abandoned
- 2002-05-30 CN CNA028132998A patent/CN1589135A/zh active Pending
- 2002-05-30 ES ES02734614T patent/ES2349349T3/es not_active Expired - Lifetime
-
2003
- 2003-11-28 ZA ZA200309306A patent/ZA200309306B/en unknown
- 2003-11-28 NO NO20035301A patent/NO20035301D0/no not_active Application Discontinuation
-
2005
- 2005-05-06 HK HK05103834.9A patent/HK1071066A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002097053A2 (fr) | 2002-12-05 |
US20030008924A1 (en) | 2003-01-09 |
JP2005515158A (ja) | 2005-05-26 |
NO20035301D0 (no) | 2003-11-28 |
NZ529792A (en) | 2007-04-27 |
ATE474568T1 (de) | 2010-08-15 |
KR20040108528A (ko) | 2004-12-24 |
EP1474121A4 (fr) | 2006-05-03 |
IL159110A0 (en) | 2004-06-01 |
DE60237115D1 (de) | 2010-09-02 |
ZA200309306B (fr) | 2006-07-26 |
MXPA03010977A (es) | 2005-04-08 |
WO2002097053A3 (fr) | 2004-09-10 |
EP1474121B1 (fr) | 2010-07-21 |
AU2002305769B2 (en) | 2007-07-19 |
CA2449245A1 (fr) | 2002-12-05 |
ES2349349T3 (es) | 2010-12-30 |
EP1474121A2 (fr) | 2004-11-10 |
SG157952A1 (en) | 2010-01-29 |
CN1589135A (zh) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071066A1 (en) | Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment | |
BR0201714A (pt) | Uso de hidroxiflavanonas para encobrir o sabor amargo | |
EP2476461A3 (fr) | Formulations pour le traitement du cancer | |
WO2004030627A3 (fr) | Methodes et compositions synergetiques pour le traitement du cancer | |
HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
EP2497478A3 (fr) | Composition d'oligosaccarides et leur utilisation dans le traitement d'infection | |
EP1181013A4 (fr) | Procede et composition pour le traitement du cancer | |
IL169897A0 (en) | Sustituted heterocycles | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
WO2007002836A3 (fr) | Procedes et compositions pour la prevention et le traitement de maladie renale | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
NO20085147L (no) | Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin | |
MX2007012623A (es) | Inulina de cadena larga. | |
TW200716088A (en) | Formulations and methods for treating amyloidosis | |
HK1083296A1 (en) | Enteral composition for the prevention and/or treatment of sepsis | |
DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
EP1773363A4 (fr) | Compositions de ngna et procédés d'utilisation de celles-ci | |
WO2006122162A3 (fr) | Procede et composition pour traiter la mucosite | |
SI1951738T1 (sl) | Nadaljnje kristalinične oblike rostafuroksina | |
PL1677818T3 (pl) | Stabilne kompozycje wodne zawierające G-CSF | |
DE602005015329D1 (de) | Rutheniumkomplexe zur krebsbehandlung | |
BRPI0410967A (pt) | compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220529 |